Trial Profile
A study to evaluate the prefrontal hemodynamic change after treatment with atomoxetine in pediatric attention-deficit/hyperactivity disorder as measured by near-infrared spectroscopy
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 30 Dec 2015
Price :
$35
*
At a glance
- Drugs Atomoxetine (Primary)
- Indications Attention-deficit hyperactivity disorder
- Focus Pharmacodynamics
- 30 Dec 2015 New trial record